Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst, Paul Baas, Dong‐Wan Kim et al. · The Lancet · 2015
Cited by 6,445 works. doi:10.1016/s0140-6736(15)01281-7
Authors
- Roy S. Herbst
- Dong‐Wan Kim
- Enriqueta Felip
- José Luis Perez‐Gracia
- Ji‐Youn Han
- Julian R. Molina
- Joo-Hang Kim
- Catherine Dubos Arvis
- Myung‐Ju Ahn
- Margarita Majem
- Mary J. Fidler
- Gilberto de Castro
- Marcelo Garrido S
- Gregory M. Lubiniecki
- Yue Shentu
- Ellie Im
- Marisa P Dolled-Filhart
- Edward B. Garon
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- The blockade of immune checkpoints in cancer immunotherapy
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
- Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer